Patients with malignant gliomas have a very poor prognosis. To explore a novel and more effective approach for the treatment of malignant gliomas, a strategy that combined tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and radiation treatment (RT) was designed in this study. Plasmid pE4-GFP was constructed by including the radioinducible early growth response gene 1 (Egr-1) promoter, and it yielded the best response with fractionated RT. Plasmid pE4-TRAIL was constructed by including the Egr-1 promoter and evaluated using U251 and U87 glioma cells. In the assay of apoptosis and killing activities, pE4-TRAIL exhibited radioresponse. pE4-TRAIL combined with RT is capable of inducing cell death synergistically. The expression of TRAIL death receptors was evaluated; which may be influenced by RT. Glioma cells with wild-type p53 showed upregulated expression of death receptors, and more synergistic effects on killing activities are expected. pE4-TRAIL was transfected into the subcutaneous U251 glioma cells in nude mice by the in vivo electroporation method. In the mice treated with pE4-TRAIL and RT, apoptotic cells were detected in pathological sections, and a significant difference of tumor volumes was observed when compared with the other groups (Po0.001). Our results indicate that radioresponsive gene therapy may have great potential as a novel therapy because this therapeutic system can be spatially or temporally controlled by exogenous RT and provides specificity and safety.
Introduction
Malignant gliomas are the most common primary brain tumors. Currently, patients with malignant gliomas have a very poor prognosis. Despite treatment with surgery, radiation and chemotherapy, the 2-year survival rate is less than 20%. 1 Some of the resistance of malignant gliomas may be attributed to glioma cells that fail to undergo apoptosis upon anticancer treatment. Therefore, a novel approach involving activation of various apoptotic signal pathways is required for the treatment of malignant gliomas. 2 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a recently identified member of the tumor-necrosis factor (TNF) ligand family, and it induces rapid apoptosis in a variety of transformed cell lines, similar to the function of the Fas ligand. 3, 4 Preclinical studies on mice and nonhuman primates have shown that systemic TRAIL administration induces apoptosis in various tumor cells and suppresses the growth of several types of tumors in animals, with little toxicity to normal cells. [5] [6] [7] [8] [9] [10] The susceptibility of tumor cells to TRAIL and an apparent lack of activity in normal cells have lead to a proposal of using TRAIL in cancer therapy. However, TRAIL was recently reported to induce apoptosis in normal human hepatocytes. 11, 12 Another study suggested that TRAIL might induce apoptosis in neurons and normal glial cells. 13 Therefore, the restriction of TRAIL expression is essential for increasing the safety of gene therapy with TRAIL.
In many studies, viral vectors have been used to increase the transfection rate; however, these vectors transduce the surrounding normal cells in a nonspecific manner. This lack of specificity is particularly problematic when viral vectors are used to deliver cytotoxic genes or suicide genes. Several strategies have been developed for the localization of cytotoxic gene therapy to tumor cells by using tissue-specific promoters; however, such localization does not produce good results consistently due to the weakness of specific promoters. 14, 15 An alternate approach for the improvement of the specificity of gene therapy involves the use of radiosensitive promoters to activate gene expression in the radiation field in a selective manner. [15] [16] [17] [18] [19] The use of a radiationinducible promoter permits the expression of a therapeutic gene to be confined within a specific irradiated volume for a chosen period of time. This tight spatial and temporal control of therapeutic gene expression potentially increases the efficiency and safety of gene therapy. We focused on the radioinducible early growth response gene 1 (Egr-1) promoter. The Egr-1 gene was initially isolated from mouse fibroblasts as an early growth response gene of the transcription factor family, like the c-fos and c-jun protooncogenes. 20 Egr-1 expression is induced in many types of cells by various mitogenic stimulations. The Egr-1 promoter contains six CArG boxes, which correspond to the radiosensitive element. 21 Therefore, the Egr-1 promoter could be effectively used in suicide gene therapy combined with radiation therapy for the regulation of the expression of tumor-sensitive genes within the targeted region. 22 Subsequently, radiation alone can sensitize some cancer cells to apoptosis via the release of cytochrome c from the mitochondria 23 and a greater number of cancer cells with wild-type p53 to TRAIL-induced apoptosis via the upregulation of the TRAIL receptor by radiation. 8 TRAIL binds to death receptors DR4 and DR5 and activates the death receptormediated apoptotic pathway. 24, 25 The combination of TRAIL and radiation may have synergistic effects on the induction of apoptosis.
On the other hand, in vivo administration of viral vectors poses problems such as antigenicity or toxicity due to the vectors. 26 Further, we tested some gene transfer systems. In this study, an in vivo electroporation system was used because it provided high efficiency of gene transfer in comparison with other nonviral transfer systems.
Materials and methods

Cell culture
Human malignant glioma U251 and U87 cells were purchased from the American Tissue Culture Collection (ATCC, Rockville, MD). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; GIBCO-BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (GIBCO-BRL) and 4 mM glutamine. Incubation was performed in a humidified atmosphere with 5% CO 2 at 371C. Exponentially growing cells were detached using 0.05% trypsin-ethylenediaminetetraacetic acid (GIBCO-BRL).
Construction of plasmids
The pCIneo plasmid (GIBCO-BRL) was used as the basis for all the vector constructs. Green fluorescent protein (GFP) cDNA was excised from the pEGFP-1 plasmid (Clontech, Basingstoke, UK) and cloned as an EcoRI/ NotI fragment into the corresponding sites in pCIneo, thereby creating pCI-GFP. The luciferase cDNA was excised from pGL3 (Promega, WI) and cloned as an Xho1/Xba1 fragment into the corresponding sites in pCIneo (creating pCI-Luc). The Egr-1 promoter was cloned as a 550 bp PCR product derived from purified HeLa DNA by using the following primers: 5 0 -TCCA GATCTCAGCCGCTCCTCCCCCGCAC-3 0 and 5 0 -AC TGCGATCGCGGGCCCGGCCCGGCCCGCATCC-3 0 , 27 which represent the À695 to À174 region of the natural promoter, containing 4 CArG elements. A total of 35 amplification cycles at 941C for 10 s, at 541C for 30 s and at 721C for 60 s were performed. The enhancer region of the cytomegalovirus gene promoter in pCIneo and pCI-GFP was replaced with the Egr-1 promoter (to produce pE4 and pE4-GFP) by using the BglII and SgfI sites at the linker ends. The cDNA of TRAIL was cloned by reverse transcription (RT)-PCR. Total cellular RNA was extracted from confluent U251 cultures (approximately 1 Â 10 7 cells) by using an RNA extraction kit (Qiagen, Hilden, Germany). U251 total RNA (1 mg) was reverse transcribed in a buffer containing 1 ml oligo-dT primers (2.5 mM), 250 mM deoxynucleotides, 10 U RNasin (Promega) and 100 U Superscript II (GIBCO-BRL). This mixture was incubated for 75 min at 371C. cDNA was amplified as follows: 1 ml (10 mM) of primer 5 0 -GCGGTCGACCA TGGCTATGATGGAGGTCCA-3 0 and 5 0 -GCGGCGG CCGCTTAGCCAACTAAAAAGGCCC-3 027 was added to 20 ml reaction volume containing 3 mM MgCl 2 , 250 mM of each deoxynucleotide and 25 U of Taq polymerase (GIBCO-BRL). The mixture was incubated first at 941C for 5 min, followed by 35 cycles denaturing at 941C for 1 min, annealing at 581C for 2 min and 721C for 4 min. The reaction was performed for an additional 4 min to ensure the completion of extension at 721C. The cDNA of TRAIL was inserted into the multicloning sites in pCIneo and pE4 (to produce pCI-TRAIL and pE4-TRAIL) by using the SalI and NotI sites at the linker ends.
In vitro transfection of DNA On the day before transfection, 2 Â 10 5 , 1Â 10 5 and 2 Â 10 4 cells were seeded into each well of 12-, 24-and 96-well culture plates. The medium was replaced by 1000, 500 and 100 ml of serum-free medium (SFM) on each well of culture plates 1 h before transfection. The cells were transfected with Lipofectamine 2000 (GIBCO-BRL) in accordance with the manufacturer's procedure. In this study, 2, 1 and 0.2 mg of plasmid DNA were mixed with 100, 50 and 10 ml of SFM, and these mixtures were incubated for 30 min at room temperature with 100, 50 and 10 ml of mixtures of SFM containing 4, 2 and 0.4 ml of liopofectamine 2000, respectively. Subsequently, each DNA-lipofectamine complex (200, 100 and 20 ml) was added to each well of the culture plates. The cells were incubated at 371C for 4 h, following which, the DNAlipofectamine complex was replaced to 1000, 500 and 100 ml diluted with DMEM containing 10% FBS. In 12-, 24-and 96-well culture plates, the rates between the numbers of seeded cells, the amount of applied plasmids, the amount of Lipofectamin 2000 and the volume of culture medium were identical.
Radiation treatment (RT)
Using a cobalt-60 g-ray source, monolayers of cells in each culture plate were irradiated at a dose rate of 0.78 Gy/min, and samples were collected at different time intervals after exposure. Mice were restricted in a special capsule and the lower parts of their bodies with tumors were irradiated using a cobalt-60 g-ray source at a dose rate of 6.02 Gy/min.
Analysis of GFP expression
The cells were analyzed for radiation-induced gene expression by quantifying the number of GFP fluorescent cells in each sample according to time intervals after RT and radiation dose. The cells were seeded and transfected in 24-well culture plates. The cells were trypsinized to obtain a single cell suspension, fixed with phosphatebuffered saline (PBS) containing 0.4% paraformaldehyde, and washed twice with 1 ml PBS by centrifugation and resuspension. Finally, the cells were resuspended in 0. 
Apoptosis assay
On day 0, 10 5 cells were seeded on a 24-well culture plate, and the plasmids were transfected on day 1. RT was administered from days 2 to 4, and the cells were then harvested using trypsin and assayed on day 5. The harvested cells were washed twice with PBS and resuspended in 100 ml of binding buffer (Pharmingen, San Diego, CA). A total of 5 ml of Annexin V-fluorescein isothiocyanate (FITC) (Pharmingen) and 10 ml of propidium iodine (Pharmingen) were added, and the mixture was incubated in the dark for 20 min at room temperature. Immediately before analysis by flow cytometry, 400 ml of binding buffer was added to each tube. Analysis was performed using the Becton Dickinson FACScan flow cytometer along with the CellQuest program (Becton Dickinson). Twenty thousand events were acquired for each analysis. In the inhibition assay, 4, 20 and 100 mM of z-VAD-fmk (carbobenzyloxy-Val-Ala-Asp (OMe) fluoromethyl ketone; R&D systems Inc., Minneapolis, MN), a general caspase inhibitor, was added to the medium immediately after transfection just before the assay.
Killing assay
On day 0, 2 Â 10 4 cells were seeded on a 96-well culture plate, and the plasmids were transfected on day 1. RT was administered from days 2 to 4. The cells were washed with PBS on days 5 and fixed using PBS containing 10% formalin for 30 min. After washing with PBS, killing activity was determined by crystal violet staining. 28 Results were expressed in terms of percent cell death, calculated as follows: (1À(OD cells treated per OD cells not treated)) Â 100. In the inhibition assay, 4, 20 and 100 mM of z-VAD-fmk was added to the medium after transfection immediately before the assay.
Expression analysis of TRAIL, DR4 and DR5
Mouse monoclonal antibodies against TRAIL (clone: RIK-2, Becton Dickinson), DR4 (TRAIL-R1, clone: 32A1380, Imgenex, San Diego, CA) and DR5 (TRAIL-R2, clone: 54B1005, Imgenex) were purchased. A total of 2 Â 10 5 cells were seeded on 12-well culture plates, and the procedures were initiated the next day. However, the transfections of the vectors were not done. The cells were harvested with trypsin in accordance with the arranged time intervals. The cells were fixed in 4% paraformaldehyde, and permeabilized in 0.1% saponin in permeabilization buffer after washing. The antibodies (1 mg) were added to 100 ml (0.1%) saponin in permeabilization buffer for 30 min at 41C. In some samples, saponin was not used, and receptors on the cell surface were detected. The cells were washed and stained using an FITC-labeled F(ab 0 ) 2 fraction (Sigma-Aldrich Inc., St Louis, MO) of affinityisolated antimouse immunoglobulin at 1/100 dilution for 30 min at 41C. After washing, the cells were analyzed using flow cytometry and the CellQuest program (Becton Dickinson). Gates containing viable cells were used to collect 10 4 events. Data are presented as the percentage of positive cells.
Animal models
During all the experiments, which were approved by the Institutional Animal Care and Use Committee, the animals were housed and handled in accordance with the guidelines of the National Institutes of Health. Human malignant glioma U251 cells (2 Â 10 6 cells in 100 ml of PBS) were inoculated subcutaneously into the left flank of 8-to 9-week-old male BALB/c nude mice. Tumor growth was monitored using a caliper twice every week. Tumor volume (V) was calculated using the formula 0.54 Â L Â W Â H, where L ¼ length (mm), W ¼ width (mm) and H ¼ height (mm). The treatment was initiated when the tumor volume reached 50-100 mm 3 .
In vivo transfection of DNA Electroporation was performed for the in vivo transfection of plasmids. The conditions for electroporation were as follows: 8 pulses of 50 ms duration at a frequency of 1 pulse/sec of electrical stimulus. The electric field strengths used were 0, 75, 150 and 225 V/cm. Under ether anesthesia, 10 mg pCI-Luc in 50 ml PBS was injected into the centers of the subcutaneous tumors. Subsequently, electroporation was performed by placing needle electrodes at both poles of the tumors. Plasmid injection and electroporation were performed once a day for 3 days, and this was repeated 3 times. Two days after the last electroporation, the mice were sacrificed, and the samples were collected. The tumor tissues were homogenized in the lysis buffer and centrifuged. The luciferase activities in the supernatant were measured using the luciferase kit (Promega). The protein concentration was measured with the micro bicinchoninic acid protein assay kit (Pierce, IL).
In vivo expression of TRAIL and detection of apoptotic cells Under ether anesthesia, 15 mg of pE4 and pE4-TRAIL in 50 ml of PBS were injected into the centers of the tumors and electroporation at 150 V/cm was performed every 24 h for 3 days. The mice were irradiated with 5 Gy/day every 24 h for 3 days starting from the next day of plasmid injection. To detect the expression of TRAIL and the induction of apoptosis, some mice were sacrificed on the day after the last RT. Total RNA was extracted from some samples with an RNA extraction kit (Qiagen). A total of 500 ng was reverse transcribed in the same condition as mentioned above. The condition of PCR and the primer design for TRAIL were also the same as mentioned above without cycles. The cycle of PCR was 20. PCR for b-actin was performed using RT-PCR primer and control set (Invitrogen, Carlsbad, CA). The other samples were fixed with 10% formaldehyde, and paraffin-embedded sections were prepared. These sections were stained using the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) technique (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Intergen, Purchase, NY) and were then counterstained with hematoxylin.
In vivo effect of TRAIL gene therapy combined with RT The xenograft model with the tumor, subcutaneously injecting U251 cells, was made according to the above methods and was treated by TRAIL gene therapy or RT. To evaluate the efficiency of this gene therapy system, the tumor volume was measured in some mice, which were divided into four groups. In the first group (n ¼ 8), the mice were treated with transfected pE4 without RT; in the second group (n ¼ 8), with pE4 and RT; in the third group (n ¼ 8), with pE4-TRAIL without RT; and in the fourth group (n ¼ 8), with pE4-TRAIL and RT.
Result
Reporter gene assay
We checked the transfection rate with pCI-GFP and flow cytometry 24 h after the transfection. A total of 1 mg of pCI-GFP was used to transfect against 10 5 cells on 24-well culture plates. The transfection rates were Radiation dose (5 Gy/day) was divided to 2.5 Gy twice/day (every 12 h). The effects of more fractioned radiation doses were evaluated using U251 cells transfected with pE4-GFP or pCI-GFP. A dose of 2.5 Gy twice/day for 1 day induced the significant response. However, the response of 2.5 Gy twice/day for 3 days decreased compared with that of 5 Gy/day for 3 days. NP, not performed; *Po0.001, **Po0.01 Student's t-test. The time course of the Egr-1 promoter expression was evaluated. We transfected 1 mg of pCI-GFP and pE4-GFP into 10 5 U251 and U87 cells on 24-well culture plates and subjected them to 5 Gy of radiation after 24 h. The number of GFP-positive cells among nonradiated cells was considered to be 1; the data were expressed as fold increases. The peak responses of pE4-GFP were observed in both U251 and U87 cells 16-24 h after RT (Figure 1a) . In pCI-GFP, no significant responses were observed against RT. U251 cells transfected with pE4-GFP and pCI-GFP were exposed to a single dose of RT of 5, 10 and 15 Gy, and fractionated dose of 5 Gy/day for 2 days and 5 Gy/day for 3 days, respectively. In the case of single doses of RT, U251 cells were assayed for GFP expression after 24 h. Response to RT was dose dependent and was observed maximally at 15 Gy in the case of single doses (Figure 1b ). In the case of fractionated doses, 5 Gy/day of RT was initiated from the day after transfection. Administration of 2 and 3 fractions of 5 Gy/day of RT required 2 and 3 days, respectively. The cells were assayed 24 h after the last RT. In U251 cells, the fractionated doses of RT induced more pE4-GFP responses than a single same dose of RT (Figure 1b) . In Figure 1c , 5 Gy/ day of RT was divided to 2.5 Gy twice/day (every 12 h), because the division to 2.5 Gy twice/day is closer to the fractioned doses of RT in clinical medicine. And the fold increases of expression of 5 Gy/day for 1 day and 5 Gy/ day for 3 days were compared with that of 2.5 Gy twice/ day for 1 day and 2.5 Gy twice/day for 3 days. Although 2.5 Gy twice/day for 1 day of RT could induce almost similar response to 5 Gy/day for 1 day, the fold increase of 2.5 Gy twice/day for 3 days was not significantly better than that of 5 Gy/day for 3 days. In our radioresponsive system, 5 Gy/day for 3 days of RT indicated the best response and was chosen.
Cytotoxicity assay A total of 1 mg of pE4-TRAIL and pCI-TRAIL was transfected into U251 and U87 cells on the 24-well culture plates in the apoptotic assay. RT was fractionated at 5 Gy/day for 3 days. In U251 and U87 cells transfected by pCI-TRAIL, RT increased the frequencies of apoptotic cells from 77.8 and 44.7 to 95.1 and 72.2% (1.22 and 1.62 times), respectively. The frequencies of apoptotic cells Figure 2 Effects of TRAIL gene therapy or RT. (a) The frequencies of apoptotic cells after gene therapies or RT. U251 and U87 cells were transfected with pCI-TRAIL or pE4-TRAIL, and RT was administered the next day (5 Gy for 3 times). The frequencies of apoptotic cells were measured on the day after the last RT. Con, negative control; RT, only radiation treatment was administered; pCI, only pCIneo was transfected, without therapeutic genes. The results shown are the average of three independent experiments. *Po0.001 Student's t-test. (b) The killing activities after gene therapies or RT. U251 and U87 cells were transfected with pCI-TRAIL or pE4-TRAIL, and RT (5 Gy for 3 times) was administered the next day. The surviving cells were quantified with crystal violet staining the day after the last RT, and the killing activities were calculated. Con, negative control; RT, only radiation treatment was administered; pCI, only pCIneo was transfected, without therapeutic genes. The results shown are the average of three independent experiments. *Po0.001, **Po0.01 Student's t-test. Figure 2b ). These data regarding killing activities indicate that pE4-TRAIL may show radio response.
Inhibition assay and TRAIL expression by radiation
To demonstrate the importance of caspase activation in the apoptosis of cells transfected with 1 mg of pE4-TRAIL on the 24-well culture plates, z-VAD-fmk, which is a general caspase inhibitor, was added to the culture medium immediately after transfection. Since z-VADfmk dissolves in dimethyl sulfoxide (DMSO), pE4-TRAIL with DMSO (25 ml of DMSO/500 ml of culture medium) in culture medium plus RT was used as the positive control. z-VAD-fmk inhibited apoptosis of U251 cells at concentrations of 100 and 20 mM and that of U87 cells at 100, 20 and 4 mM (Figure 3a ). This result indicates that pE4-TRAIL with RT could induce apoptosis in cells via the activation of the caspase cascade. A total of 2 mg of pE4-TRAIL was transfected to U251 cells on the 12-well culture plates. It was confirmed that RT induced an increase in the amount of the TRAIL protein in the transfected U251 cells (Figure 3b) . In this experiment, a single radiation dose of 15 Gy was administered. A peak of the TRAIL protein was observed 4 h after RT, and the frequency of TRAIL proteinpositive cells increased from 9.6 to 26.1%. These findings regarding inhibition assays and induction of the TRAIL protein confirmed that the TRAIL protein could induce apoptosis via the activation of caspase cascade in pE4-TRAIL with RT.
Expression of DR4 and DR5
In some cancer cells, combined therapy of TRAIL and RT has been reported to induce a synergistic effect on apoptosis. This phenomenon may be attributed to the upregulation of TRAIL receptors by RT. We evaluated the influence of RT on the expression of TRAIL receptors. A single dose or fractionated doses of RT were administered, and the frequencies of the receptor-positive cells were measured after 24 h. In U251 cells, DR4 (Figure 4a ) and DR5 (Figure 4b ) decreased after RT. In U87 cells, DR4 started increasing at 24 h after RT and reached a peak at 72 h ( Figure 4c) ; DR5 also increased during this period (Figure 4d) . In some glioma cells with upregulation of TRAIL receptors, a synergistic effect could be expected by combination treatment of pE4-TRAIL with RT. Recently, it has been reported that transactivation of these receptors is directly regulated by exogenous or endogenous wild-type p53; recent reports established these receptors as a p53 target gene capable of signaling apoptotic death. Therefore, U87 cells that have wild-type p53 are capable of increasing the expression of TRAIL receptors. However, U251 cells have mutated p53 and therefore cannot increase the expression of TRAIL receptors.
In vivo electroporation expression of luciferase The activity of luciferase was measured from the samples of tumor tissues and revised in accordance with the protein concentration of each sample. Electroporation Figure 3 Inhibition assay of caspase cascade and expression of TRAIL by RT. (a) Inhibition assay using z-VAD-fmk, a general caspase inhibitor. RT, only radiation treatment was performed; Lipo þ RT, Lipofectamine 2000 was added to the medium and radiation treatment was performed. pE4-TRAIL þ RT, pE4-TRAIL was transfected and radiation treatment was performed. DMSO was added to the medium of pE4-TRAIL þ RT (25 ml of DMSO/500 ml of the culture medium) because z-VAD-fmk is soluble in DMSO. A caspase inhibitor was added to the medium of pE4-TRAIL þ RT þ DMSO up to 100, 20 and 4 mM of final concentration of z-VAD-fmk. The results shown are the average of three independent experiments. *Po0.001, **Po0.01 Student's t-test. Student's t-test, Po0.01, n ¼ 3). We selected a field strength of 150 V/cm for in vivo electroporation; extensive necrotic areas were observed in tumor sections when electroporation was performed with a field strength of 225 V/cm. Electroporation performed at a high voltage may induce necrosis in tumor cells, resulting in the failure to detect luciferase expression.
TRAIL expression in vivo and the apoptotic cells in the tumors Xenograft models were made by subcutaneously injecting U251 cells in BALB/c nude mice, and were treated by TRAIL gene therapy or RT. Plasmid injection and electroporation were performed on days 1, 2 and 3, while RT was administered on days 2, 3 and 4. The expression was detected with RT-PCR on day 5. In pE4-TRAIL transfection alone and pE4-TRAIL transfection combined with RT, the bands of TRAIL were observed at 20 cycles. In pE4 transfection alone and pE4 transfection combined with RT, no band at 20 cycles was observed (Figure 6a ). The band intensity of pE4-TRAIL with RT looks stronger than that of pE4-TRAIL alone, which means that pE4-TRAIL may respond to RT (Figure 6a ). Some samples were collected on day 5. A few apoptotic cells were observed in the pathological sections that were treated by pE4-TRAIL transfection alone and by pE4 transfection combined with RT (Figure 6b ). In the pathological section treated by pE4-TRAIL transfection combined with RT, lots of apoptotic cells were detected (Figure 6b ). pE4-TRAIL with RT was believed to be effective in inducing apoptosis in tumor cells. TRAIL gene therapy combined with RT for the animal model Xenograft models were made and were treated with the same methods. Plasmid injection and electroporation were performed on days 1, 2 and 3, while RT on days 2, 3 and 4. The tumors grew rapidly in the groups treated by pE4 transfection and pE4-TRAIL transfection (Figure 6c ). In the group treated by pE4 transfection and RT, transient regression of the tumors was observed, but regrowth was finally observed. In the group treated by Figure 6 Radioresponsive TRAIL gene therapy H Tsurushima et al pE4-TRAIL and RT, the size of the tumors consistently decreased after day 7 (Figure 6c ), and regrowth of tumors was not observed on day 39. A significant difference in tumor sizes was observed between the two groups: 7.876.6 mm 3 , pE4-TRAIL with RT and 6147220 mm 3 , pE4 with RT (Student's t-test, Po0.001, n ¼ 8). In conclusion, regrowth of tumors was not observed till day 50 when the mice were sacrificed.
Discussion
Based on many animal experiments, it is believed that the TRAIL protein is capable of inducing apoptotic cell death in many types of transformed cells, but not in normal cells. [5] [6] [7] [8] [9] [10] Therefore, systemic administration of TRAIL was expected to be one of the most promising candidates in cytokine therapy against cancer. However, in some experiments using primary cultured human hepatocytes, it was confirmed that TRAIL was capable of inducing apoptosis in normal hepatocytes. 11, 12 Another study using a section culture of normal human brain confirmed that 400 ng/ml TRAIL induced apoptosis in the cells of the brain section. 13 However, it has been reported that TRAIL cannot induce apoptosis in a primary culture of astrocytes. 10 Systemic administration of TRAIL and its application to the brain are controversial. However, TRAIL is one of the strongest apoptosis inducers and shows great promise as a candidate for anticancer drugs because TRAIL is surmised to possess lower toxicities than some death ligands such as TNF-a and Fas ligand. 29 To increase the safety of TRAIL therapy, the delivery of TRAIL should be localized to the lesion. Controlling of expression of the therapeutic protein is unavoidable and can ensure a high level of safety in this treatment system. The Egr-1 promoter, which has been described as a radiosensitive promoter, was used in our treatment system. [15] [16] [17] [18] [19] The expression of a therapeutic gene controlled by the Egr-1 promoter could be regulated by ionizing radiation in temporal, spatial and dose-dependent manners. In our study, it was interesting that fractioned RT was more effective in activating the Egr-1 promoter than single treatment with the same dose, although 2.5 Gy twice/day for 3 days of RT, whose schedule of RT was close to that of clinical medicine, could not induce the best response. This method may be useful in clinical medicine because fractioned RT is immensely popular in clinical medicine. In our system, TRAIL activates the caspase cascade via caspase-8 and radiation simultaneously activates it via caspase-9. Finally, our system may be considered to produce a synergistic or additive effect on inducing apoptosis, and such an effect may contribute to a good response of our system for RT.
TRAIL induces apoptosis by binding to two proapoptotic receptors, namely DR4 and DR5. 24, 25 Recently, it has been reported that transactivation of these receptors is directly regulated by exogenous or endogenous wildtype p53 and established these receptors as a p53 target gene that can signal apoptotic death. 25, 30 In malignant gliomas with wild-type p53, such as U87 cells, synergistic effects may be expected by combination therapy with RT and TRAIL.
Some in vivo nonviral transfection methods such as calcium phosphate coprecipitation, lipofectin transfection, particle bombardment and electroporation have been developed. In vivo transfection remains a major problem. Electroporation of cell membranes has been developed for achieving highly efficient in vitro gene transfer and/or drug transfer. 31, 32 In recent studies, electroporation was used in vivo to study the effects of cytokine gene transfection on experimental murine tumors. 33, 34 The gene transfection efficiency of electroporation was reported to be approximately 25-30%. 35 Plasmid injection and electroporation in vivo were then performed three times to obtain a higher efficiency of electroporation. In our experiments, our radioresponsive plasmid, which was transferred in vivo to the subcutaneous tumor by electroporation, induces extensive apoptosis based on RT, and tumor growth was finally suppressed. Electroporation may prove to be one of the most efficient gene transfer methods in the clinical application of gene therapy, provided solutions can be obtained for certain problems such as the setting of electrodes in vivo.
Our results indicate that radioresponsive gene therapy may have great potential as a novel therapy because this therapeutic system can be spatially or temporally controlled by exogenous RT and provides specificity and safety. 36 
Figure 6
Effects of pE4-TRAIL with RT. Xenograft models were made by injecting U251 cells in BALB/c nude mice, and were treated by TRAIL gene therapy or RT. A total of 15mg of pE4 or pE4-TRAIL was injected into the tumors, and electroporation was performed every 24 h for 3 days. Next, the tumors were irradiated at 5 Gy/day every 24 h for 3 days from the day after the first electroporation. (a) The expression of TRAIL was detected by RT-PCR. Samples were collected on day 5. The band intensity of TRAIL was the strongest in pE4-TRAIL with RT, and the next was in pE4-TRAIL alone. No band was observed in pE4 alone and pE4 with RT. The cycle of PCR was 20. (b) The frequencies of apoptotic cells after pE4-TRAIL or RT. Samples were collected on day 5, and apoptotic cells were detected by TUNEL staining. pE4-TRAIL, electroporation of pE4-TRAIL was performed. pE4 þ RT, electroporation of pE4 (without TRAIL) and RT. pE4-TRAIL þ RT, electroporation of pE4-TRAIL and RT. A lot of apoptotic cells were observed after pE4-TRAIL þ RT and a few apoptotic cells after RT; or pE4-TRAIL alone. Magnification Â 200. (c) Tumor growth. Four groups were created: electroporation of pE4 (n ¼ 8), electroporation of pE4-TRAIL (n ¼ 8), electroporation of pE4 with RT (n ¼ 8) and electroporation of pE4-TRAIL with RT (n ¼ 8). In the first two groups, the tumors grew rapidly. In the pE4 with RT, tumors reduced temporally, but finally grew to 6147220 mm 3 on day 39. In the pE4-TRAIL with RT, the size of the tumors reduced after therapy, and regrowth was not observed. The final tumor size was 7.876.63 mm 3 . *Po0.001, Student's t-test.
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